Get the Stockscreener App
9.01
0.45%
0.04
After Hours:
9.17
0.16
+1.78%
Kura Oncology Inc stock is traded at $9.01, with a volume of 3.03M.
It is up +0.45% in the last 24 hours and down -43.37% over the past month.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
See More
Previous Close:
$8.97
Open:
$8.92
24h Volume:
3.03M
Relative Volume:
2.14
Market Cap:
$700.65M
Revenue:
-
Net Income/Loss:
$-168.09M
P/E Ratio:
-4.3951
EPS:
-2.05
Net Cash Flow:
$-138.01M
1W Performance:
-6.44%
1M Performance:
-43.37%
6M Performance:
-55.66%
1Y Performance:
-27.04%
1-Day Range:
$8.88
$9.17
1-Week Range:
$8.85
$10.02
52-Week Range:
$8.85
$24.17
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Compare KURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
9.01 | 700.65M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-14-24 | Downgrade | Stifel | Buy → Hold |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Aug-11-23 | Initiated | BofA Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| May-17-23 | Initiated | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-15-22 | Initiated | Jefferies | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| May-05-20 | Initiated | Barclays | Overweight |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Nov-09-18 | Initiated | Piper Jaffray | Overweight |
| Aug-01-18 | Initiated | H.C. Wainwright | Buy |
| Oct-13-16 | Resumed | Leerink Partners | Outperform |
| Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-30-15 | Initiated | Oppenheimer | Outperform |
| Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
Kura Oncology expands stock option plan - Investing.com
Kura Oncology (NASDAQ:KURA) Reaches New 52-Week LowWhat's Next? - MarketBeat
Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade) (NASDAQ:KURA) - Seeking Alpha
(KURA) Proactive Strategies - Stock Traders Daily
Kura Oncology's SWOT analysis: ziftomenib's promise buoys stock outlook By Investing.com - Investing.com UK
Kura Oncology's SWOT analysis: ziftomenib's promise drives stock outlook By Investing.com - Investing.com South Africa
Kura Oncology's SWOT analysis: ziftomenib's promise drives stock outlook - Investing.com India
Kura Oncology's SWOT analysis: ziftomenib's potential reshapes cancer stock landscape - Investing.com Canada
Kura Oncology’s (KURA) Overweight Rating Reaffirmed at Cantor Fitzgerald - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2024 Earnings Call Transcript - MSN
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting - The Manila Times
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib At American Society of Hematology Annual Meeting - Marketscreener.com
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in Kura O - GuruFocus.com
Purple Biotech Secures $2.8 Million for Oncology Advancements - MSN
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Why Is Kura Oncology, Inc. (KURA) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Insider Monkey
Kura Oncology Inc (NASDAQ: KURA) Gains 1.45% In Early Trade; What Lies Ahead? - Stocks Register
Kura Oncology to Host Virtual Investor Event on December 9, 2024 - The Manila Times
Kura Oncology to Host Investor Event on Ziftomenib Clinical Trial Data from ASH Meeting | KURA Stock News - StockTitan
ImmuneOnco Raises Funds for Cancer Research - MSN
Kura Oncology price target raised to $37 from $32 at H.C. Wainwright - MSN
Kura Oncology’s Collaboration with Kyowa Kirin - Global Legal Chronicle
How to Take Advantage of moves in (KURA) - Stock Traders Daily
Kura Oncology's SWOT analysis: precision cancer drug stock faces pivotal year - Investing.com India
Kura, Kyowa Kirin to co-develop ziftomenib in $1.49B deal - BioWorld Online
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit - The Manila Times
Kura Oncology CEO to Present at JMP Securities Hematology & Oncology Summit | KURA Stock News - StockTitan
Cantor Fitzgerald Reaffirms Overweight Rating for Kura Oncology (NASDAQ:KURA) - Defense World
Kura Oncology (NASDAQ:KURA) Given Buy Rating at TD Cowen - Defense World
FY2025 EPS Estimate for Kura Oncology Raised by Analyst - Defense World
Leerink Partnrs Predicts Stronger Earnings for Kura Oncology - MarketBeat
Kura Oncology (NASDAQ:KURA) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
Brokers Offer Predictions for Kura Oncology FY2025 Earnings - MarketBeat
Bank of America Issues Pessimistic Forecast for Kura Oncology (NASDAQ:KURA) Stock Price - Defense World
Kura Oncology partners Kyowa Kirin to advance AML treatment - MSN
Kura Crashes 37% After $1.53 Billion Deal Slams The Door On A Takeover - MSN
Kura Oncology (NASDAQ:KURA) Sees Large Volume Increase on Analyst Upgrade - MarketBeat
Kura Oncology, Inc. (KURA): Among the Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
Stifel cuts Kura Oncology target to $11 from $18, holds rating - Investing.com Canada
Firm Advises Kura Oncology on Global Strategic Collaboration with Kyowa Kirin - Wilson Sonsini
10 Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
Kura Oncology Stock Slips Following Collaboration With Kyowa: Retail Turns Extremely Bullish - MSN
Kura Oncology (NASDAQ:KURA) Given New $29.00 Price Target at Bank of America - MarketBeat
Earnings call: Kura Oncology reports on ziptamenib's progress in Q3 By Investing.com - Investing.com South Africa
Kura Oncology (NASDAQ:KURA) Shares Gap Down on Analyst Downgrade - Defense World
Earnings call: Kura Oncology reports on ziptamenib's progress in Q3 - Investing.com India
Kura Oncology inks global deal with Kyowa Kirin By Investing.com - Investing.com Nigeria
Analysts supportive of Kura/Kirin deal despite major selloff (update) - MSN
Health Care Roundup: Market Talk - MSN
Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin - MedCity News
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):